Use Cases
Metabolic Health
Visceral Fat and Metabolic Markers
Not weight on a scale, but the fat around the organs — the compartment most strongly tied to metabolic risk.
CEarly Human ResearchReviewed September 1, 2026
Compounds used for this goal
The reason
Why people use it
- Visceral fat tracks with insulin resistance and cardiovascular risk more closely than total weight, so people with normal weight and poor markers focus on it specifically.
- Tesamorelin is the only compound here with a trial-supported, imaging-measured visceral fat reduction.
- 5-Amino-1MQ is discussed as an NNMT inhibitor intended to act on fat cell metabolism, and AOD-9604 as a growth hormone fragment intended to isolate lipolysis from growth effects.
The evidence
What the research shows
- Tesamorelin's randomised trials reported visceral adipose tissue reduction on imaging in HIV-associated lipodystrophy, with regain after stopping.
- AOD-9604 is the cautionary tale of this category: it reached human obesity trials and failed to show meaningful weight loss versus placebo, yet is still marketed on preclinical rationale.
- 5-Amino-1MQ has interesting animal metabolic data and essentially no published human trial evidence.
- Where visceral fat has been reduced in trials, the effect reversed after discontinuation.
Reported use
How it is reported to be used
- Tesamorelin is reported as a daily evening subcutaneous injection, matching its approved administration.
- Reported use runs in months rather than weeks, because visceral fat change is only detectable over that timescale.
- Injection-site reactions and joint aches are the most reported complaints with tesamorelin.
Our reading
Evidence verdict
CEarly Human ResearchSmall, early-phase or single-centre human studies only. Findings are preliminary.
Early human research, with one genuinely trial-supported compound and one that has already failed its human trials.
Before you read further
Cautions and open questions
- AOD-9604 failing in human trials is published evidence of absence of effect, not merely absence of evidence.
- Growth hormone axis stimulation can worsen glucose control, which is counterproductive if metabolic markers are the goal.
- Visceral fat responds substantially to sleep, alcohol reduction, resistance training and diet quality — interventions with far better evidence.
Sources
Referenced research
- Randomised controlled trial
Tesamorelin effects on visceral adipose tissue
- Randomised controlled trial
AOD-9604 human obesity trial outcomes
- Main finding
- Reported no clinically meaningful weight reduction versus placebo.
Educational content only. This page is not medical advice, a protocol or an individualised dosing recommendation. Reported use patterns summarise published literature and community reporting; they are not verified clinical cases and are not endorsements. Speak to a qualified healthcare professional about your own health.
All use cases